Summary: AbbVie’s Q1 2023 global net revenues totaled $12.225 billion, marking a 9.7% decrease from
Summary: AbbVie stock has been upgraded to a buy again due to its attractive yield
Summary: AbbVie’s growth prospects remain strong despite the impending decline in revenue from Humira, thanks
Summary: AbbVie Inc.’s share price has been slipping as its globally best-selling drug Humira has
Summary: AbbVie stock is down 10% after Q1 earnings. The mixed-bag quarter offered clarity on
Summary: Herbicides have been linked to irritable bowel syndrome. The incidence of irritable bowel syndrome
Summary: Many investors do not consider Peter Lynch to be a dividend investor – an
Summary: AbbVie dropped almost 8% after its most recent earnings release, which was triggered by
Summary: Both Gilead and AbbVie are strong picks for dividend investors. Ailing cash cows are
Summary: AbbVie’s revenue amounted to $12,225 million in the first three months of 2023, 9.7%